Evidence map›Paper›PMID 30089152›Full record

ArticlePLoS pathogens2018

Prion acute synaptotoxicity is largely driven by protease-resistant PrPSc species.

Simote Totauhelotu Foliaki, Victoria Lewis, David Isaac Finkelstein, Victoria Lawson, Harold Arthur Coleman, Matteo Senesi, Abu Mohammed Taufiqual Islam, Feng Chen, Shannon Sarros, Blaine Roberts and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Quaternary Structure Changes for PrPMolecular neurobiology · 2021
    Article
  9. Highly infectious prions are not directly neurotoxic.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Simote Totauhelotu FoliakiDepartment of Medicine (Royal Melbourne Hospital), The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0001-7450-6926
Victoria LewisDepartment of Medicine (Royal Melbourne Hospital), The University of Melbourne, Parkville, Victoria, Australia.
David Isaac FinkelsteinFlorey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.ORCID 0000-0002-8167-4917
Victoria LawsonDepartment of Pathology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-7362-7176
Harold Arthur ColemanFlorey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.
Matteo SenesiDepartment of Medicine (Royal Melbourne Hospital), The University of Melbourne, Parkville, Victoria, Australia.
Abu Mohammed Taufiqual IslamDepartment of Medicine (Royal Melbourne Hospital), The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-9716-6351
Feng ChenFlorey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.
Shannon SarrosFlorey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.
Blaine RobertsFlorey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.
Paul Anthony AdlardFlorey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.
Steven John CollinsDepartment of Medicine (Royal Melbourne Hospital), The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-5245-6611
Florey Institute of Neuroscience and Mental Health · AUThe Royal Melbourne Hospital · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although misfolding of normal prion protein (PrPC) into abnormal conformers (PrPSc) is critical for prion disease pathogenesis our current understanding of the underlying molecular pathophysiology is rudimentary. Exploiting an electrophysiology paradigm, herein we report that at least modestly proteinase K (PK)-resistant PrPSc (PrPres) species are acutely synaptotoxic. Brief exposure to ex vivo PrPSc from two mouse-adapted prion strains (M1000 and MU02) prepared as crude brain homogenates (cM1000 and cMU02) and cell lysates from chronically M1000-infected RK13 cells (MoRK13-Inf) caused significant impairment of hippocampal CA1 region long-term potentiation (LTP), with the LTP disruption approximating that reported during the evolution of murine prion disease. Proof of PrPSc (especially PrPres) species as the synaptotoxic agent was demonstrated by: significant rescue of LTP following selective immuno-depletion of total PrP from cM1000 (dM1000); modestly PK-treated cM1000 (PK+M1000) retaining full synaptotoxicity; and restoration of the LTP impairment when employing reconstituted, PK-eluted, immuno-precipitated M1000 preparations (PK+IP-M1000). Additional detailed electrophysiological analyses exemplified by impairment of post-tetanic potentiation (PTP) suggest possible heightened pre-synaptic vulnerability to the acute synaptotoxicity. This dysfunction correlated with cumulative insufficiency of replenishment of the readily releasable pool (RRP) of vesicles during repeated high-frequency stimulation utilised for induction of LTP. Broadly comparable results with LTP and PTP impairment were obtained utilizing hippocampal slices from PrPC knockout (PrPo/o) mice, with cM1000 serial dilution assessments revealing similar sensitivity of PrPo/o and wild type (WT) slices. Size fractionation chromatography demonstrated that synaptotoxic PrP correlated with PK-resistant species >100kDa, consistent with multimeric PrPSc, with levels of these species >6 ng/ml appearing sufficient to induce synaptic dysfunction. Biochemical analyses of hippocampal slices manifesting acute synaptotoxicity demonstrated reduced levels of multiple key synaptic proteins, albeit with noteworthy differences in PrPo/o slices, while such changes were absent in hippocampi demonstrating rescued LTP through treatment with dM1000. Our findings offer important new mechanistic insights into the synaptic impairment underlying prion disease, enhancing prospects for development of targeted effective therapies.

Indexed as

Acute DiseaseAnimalsBrain DiseasesEndopeptidase KFemaleMiceMice, Inbred C57BLMice, KnockoutPrion DiseasesPrionsProteolysisPrPC ProteinsSynapsesEndopeptidase KPrionsPrPC Proteins

Identifiers

PMID30089152
PMCPMC6101418
OpenAlexW2886044850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.